Oncorus, Inc.: Nasdaq/NYSE listing notice — Oncorus gets 180-day Nasdaq extension; stock moves to Capital Market

Oncorus, Inc.

Nasdaq granted extension until October 30, 2023 to meet $1.00 minimum bid price rule.
Oncorus common stock transferred from Nasdaq Global Market to Capital Market effective May 3, 2023.
To regain compliance, closing bid price must be $1.00+ for 10 consecutive business days.
Company may consider reverse stock split; failure could lead to delisting and appeal process.
CEO Ted Ashburn signed the filing; no assurance of regaining compliance stated.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Oncorus, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

May 2, 2023, Oncorus, Inc. (the “ Company ”) received a notice (the “ Extension Notice ”) from the Listing Qualifications Department of the Nasdaq Stock Market (“ Nasdaq ”) informing the Company that Nasdaq granted the Company an additional 180 calendar days, or until October 30, 2023, to regain compliance with the minimum closing bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “ Rule ”). In connection with the Extension Notice, the listing of the Company’s common stock was transferred from the Nasdaq Global Market to the Nasda

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0000950170-23-018381

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.